Skip to content
Triangle logo TriangleGet started
← Zydelig: recurrent non-Hodgkin lymphoma after prior therapy

NCT00054639 · STUDY IN CONTEXT

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment

Analysis was per protocol. Of the 48 participants enrolled, only 42 were evaluable for response.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00054639
trial label
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
applicability
unclear
applicability note
Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
1
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-zydelig-b71fbc34
    nct id
    NCT00054639
    outcome key
    om-0000
    source section id
    NCT00054639-om-0000
    source outcome index
    0
    endpoint
    Number of Patients With Objective Response
    endpoint definition
    Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment
    time origin
    2 months following study treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Analysis was per protocol. Of the 48 participants enrolled, only 42 were evaluable for response.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-zydelig-b71fbc34
    nct id
    NCT00054639
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Oblimersen + Rituximab
    regimen
    Oblimersen 3 mg/kg/day continuous intravenous infusion daily for 7 days on alternated weeks on week 1, 3 and 5 (days 1 through 7, 15 through 21, and 29 through 35); Rituximab 375 mg/m2 intravenous infusion for six doses on days 3, 8,15, 22, 29, and 36.
    analyzed count
    42
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00054639-om-0000#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-zydelig-b71fbc34
    nct id
    NCT00054639
    harm key
    EG000
    source section id
    NCT00054639-ae
    event group key
    EG000
    event group label
    Oblimersen + Rituximab
    serious affected
    15
    serious at risk
    46
    other affected
    46
    other at risk
    46
    frequency threshold
    5
    collection period
    2 Years, 10 Months
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice